Protagonist Therapeutics, Inc. (PTGX) Q3 2019 Earnings Results

Protagonist Therapeutics Misses on EPS, Stock Down 5.77%

The earnings report indicates that Protagonist Therapeutics is still in a challenging phase, as evidenced by the missed EPS. The stock fell by 5.77% following the announcement, reflecting investor concerns over the lack of revenue details and future guidance. The focus remains on their clinical trials, but uncertainty may weigh on investor sentiment.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.61	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding future performance. They highlighted the importance of their clinical programs but did not provide specific guidance.

Management did not provide specific insights on revenue expectations.

The company remains focused on its ongoing clinical trials.

Protagonist Therapeutics Misses on EPS, Stock Down 5.77%

Key numbers

Management commentary

Protagonist Therapeutics, Inc.

More earnings this week

Protagonist Therapeutics Misses on EPS, Stock Down 5.77%

Key numbers

Management commentary